[1] Tyczynski J E, Bray F, Parkin D M. Lung cancer in Europe in 2000: epidemiology, prevention, and early detection [J]. Lancet Oncol, 2003, 4(1): 45 [2] Van Meerbeeck J P, Fennell D A, De Ruysscher D K. Small-cell lung cancer [J]. Lancet, 2011, 378(9804): 1741 [2] Rom W N, Hay J G, Lee T C, et al. Molecular and genetic aspects of lung cancer [J]. Am J Respir Crit Care Med, 2000, 161(4 Pt 1): 1355 ?[3] Fischer B, Arcaro A. Current status of clinical trials for small cell lung cancer [J]. Rev Recent Clin Trials, 2008, 3(1): 40 ?[4] Sattler M, Salgia R. Molecular and cellular biology of small cell lung cancer [J]. Semin Oncol, 2003, 30(1): 57 [5] Semenova E A, Nagel R, Berns A. Origins, genetic landscape, and emerging therapies of small cell lung cancer [J]. Genes Dev, 2015, 29(14): 1447 [6] Kamangar F, Dores G M, Anderson W F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world [J]. J Clin Oncol, 2006, 24(14): 2137 [7] Linnoila R I. Functional facets of the pulmonary neuroendocrine system [J]. Lab Invest, 2006, 86(5): 425 [8] Huun J, Lonning P E, Knappskog S. Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines [J]. Cell Death Discov, 2017, 3:17026 [9] Meuwissen R, Linn S C, Linnoila R I, et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model [J]. Cancer Cell, 2003, 4(3): 181 [10] Donehower L A. The p53-deficient mouse: a model for basic and applied cancer studies [J]. Semin Cancer Biol, 1996, 7(5): 269 [11] Lee J K, Lee J, Kim S, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas [J]. J Clin Oncol, 2017, 12:JCO2016719096 [12] Abe R, Donnelly S C, Peng T, et al. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites [J]. J Immunol, 2001, 166(12): 7556